Strategic Transactions & Market Disruptors

Alvotech and Teva's settlement with Regeneron for an Eylea biosimilar paves the way for a 2026 launch, promising increased competition and lower costs.

A new settlement positions a cost-effective alternative to the blockbuster eye drug Eylea for a 2026 U.S. launch, signaling intense market disruption.

Nova Minerals is raising $20M to advance its Estelle Project, a key Alaskan site for gold and the strategically vital mineral antimony amid global supply woes.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

A monumental shift in U.S. drug policy as cannabis is rescheduled. See what this means for Verano, Wall Street, and the future of the industry.

Facing financial headwinds, Celularity lands a critical $12M from a top investor to push its ambitious anti-aging and regenerative therapies forward.

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.

Picard Medical rings the NYSE bell, but its stock's volatile journey reflects the high-stakes gamble on its next-generation artificial heart technology.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.

Asia Pacific Wire & Cable is raising $33.9M via a rights offer to fund its US expansion. Shareholders must now weigh participation against dilution risk.

Etsy is backing its next chapter with a massive share repurchase and a fortified board, as Kruti Patel Goyal prepares to take the CEO reins.

With FDA approval for a pivotal study, Pulse Biosciences' novel nanosecond ablation technology aims to make atrial fibrillation treatment safer and more precise.

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.

Completing a key mission 5 months early, Rocket Lab deployed novel DiskSat tech, cementing its role in the U.S. military's agile space strategy.

With FDA & EMA alignment, atebimetinib heads to a Phase 3 trial, offering new hope against deadly pancreatic cancer based on promising early survival data.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

With a former U.S. CTO, WHO expert, and life sciences vet, Welldoc is assembling a powerhouse team to dominate the AI-driven cardiometabolic care market.

As AI agents reshape e-commerce, a new HUMAN and AWS partnership aims to secure them with cryptographic verification, building a foundation for trusted automation.

New rankings name Germany's top cancer hospitals, but the real story is the rise of platforms shaping a multi-billion dollar global health market.

A new FDA clearance for its AI software enhances Hyperfine's portable MRI, positioning it to disrupt the lucrative stroke diagnostics market. Here's why.